Impact of pharmacodynamics on breakpoint selection for susceptibility testing (Q35623076)

9 August 2017

1 reference

title

Impact of pharmacodynamics on breakpoint selection for susceptibility testing (English)

1 reference

9 August 2017

1 reference

1

Johan W Mouton

1 reference

9 August 2017

publication date

1 September 2003

1 reference

Infectious Disease Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

579-598

1 reference

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Kinetics of antimicrobial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Bactericidal dosie-activity relationships with E. coli, K. pneumoniae and Staph. aureus (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of fluoroquinolones in experimental models of endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Breakpoints: current practice and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

The Relation of Protein Binding to the Pharmacology and Antibacterial Activity of Penicillins X, G, Dihydro F, and K.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Influence of binding on the pharmacologic activity of antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Antibiotic assays in muscle: are conventional tissue levels misleading as indicator of the antibacterial activity?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

A problem in the interpretation of beta-lactam antibiotic levels in tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Does serum protein binding inhibit tissue penetration of antibiotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

A brief introduction to Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial a

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. The Comité de l'Antibiogramme de la Société Française de Microbiologie.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900062-X

7 January 2021

10.1016/S0891-5520(03)00062-X

Identifiers

DOI

1 reference

9 August 2017

1 reference